Smallpox vaccine

The smallpox vaccine is used to prevent smallpox infection caused by the variola virus.

Uses your system voice; voice and rate in settings.

≈ 5 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

The smallpox vaccine is used to prevent smallpox infection caused by the variola virus. It is the first vaccine to have been developed against a contagious disease. In 1796, British physician Edward Jenner demonstrated that an infection with the relatively mild cowpox virus conferred immunity against the deadly smallpox disease.

Cowpox served as a natural vaccine until the modern smallpox vaccine emerged in the 20th century. From 1958 to 1977, the World Health Organization (WHO) conducted a global vaccination campaign that eradicated smallpox, making it the only human disease to be eradicated.

Although routine smallpox vaccination is no longer performed on the general public, the vaccine is still being produced for research, and to guard against bioterrorism and biological warfare. The term vaccine derives from vacca, the Latin word for cow, reflecting the origins of smallpox vaccination. Edward Jenner referred to cowpox as variolae vaccinae (smallpox of the cow).

The origins of the smallpox vaccine became murky over time, especially after Louis Pasteur developed laboratory techniques for creating vaccines in the 19th century. Allan Watt Downie demonstrated in 1939 that the modern smallpox vaccine was serologically distinct from cowpox, and vaccinia was subsequently recognized as a separate viral species.

Whole-genome sequencing has revealed that vaccinia is most closely related to horsepox, and the cowpox strains found in Great Britain are the least closely related to vaccinia. The smallpox vaccine has also proven useful in preventing emergent infectious diseases caused by closely-related orthopoxviruses such as Mpox.

Three specific smallpox vaccines have been approved in at least one country for Mpox prevention: MVA-BN, LC16m8, and ACAM2000. The Mpox vaccine is on the World Health Organization's List of Essential Medicines.

First-generation

The first-generation vaccines are manufactured by growing live vaccinia virus in the skin of live animals. Most first-generation vaccines are calf lymph vaccines that were grown on the skin of cows, but other animals were also used, including sheep.

The development of freeze-dried vaccine in the 1950s made it possible to preserve vaccinia virus for long periods of time without refrigeration, leading to the availability of freeze-dried vaccines such as Dryvax. The vaccine is administered by multiple puncture of the skin (scarification) with a bifurcated needle that holds vaccine solution in the fork.

The skin should be cleaned with water rather than alcohol, as the alcohol could inactivate the vaccinia virus. If alcohol is used, it must be allowed to evaporate completely before the vaccine is administered. Vaccination results in a skin lesion that fills with pus and eventually crusts over.

This manifestation of localized vaccinia infection is known as a vaccine "take" and demonstrates immunity to smallpox. After 2–3 weeks, the scab will fall off and leave behind a vaccine scar. First generation vaccines consist of live, unattenuated vaccinia virus.

One-third of first-time vaccinees develop side effects significant enough to miss school, work, or other activities, or have difficulty sleeping. 15–20% of children receiving the vaccine for the first time develop fevers of over . The vaccinia lesion can transmit the virus to other people.

Rare side effects include postvaccinal encephalitis and myopericarditis. Many countries have stockpiled first generation smallpox vaccines.

In a 2006 predictive analysis of casualties if there were a mass vaccination of the populations of Germany and the Netherlands, it was estimated that a total of 9.8 people in the Netherlands and 46.2 people in Germany would die from uncontrolled vaccinia infection after being vaccinated with the New York City Board of Health strain. More deaths were predicted for vaccines based other strains: Lister (55.1 Netherlands, 268.5 Germany) and Bern (303.5 Netherlands, 1,381 Germany).

MVA-BN

MVA-BN (brand names: Imvanex, Imvamune, and Jynneos) is a modified vaccinia Ankara (MVA) vaccine manufactured by Bavarian Nordic by growing MVA in cell culture. Unlike replicating vaccines, MVA-BN is administered by injection via the subcutaneous route and does not result in a vaccine "take."

A "take" or "major cutaneous reaction" is a pustular lesion or an area of definite induration or congestion surrounding a central lesion, which can be a scab or an ulcer. MVA-BN can also be administered intradermally to increase the number of available doses. It is safer for immunocompromised patients and those who are at risk from a vaccinia infection.

MVA-BN has been approved in the European Union, Canada, and the United States. Clinical trials have found that MVA-BN is safer and just as immunogenic as ACAM2000. This vaccine has also been approved for use against mpox.

It received WHO prequalification against smallpox and Mpox in September 2024.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378715331 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001378715331 · captured 2026-10-05 · ledger · version history

Cite this page as: encyclopegia.org, “Smallpox vaccine”, snapshot enwiki-001378715331. https://encyclopegia.org/a/smallpox-vaccine

Sources cited in this revision

21 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.